January 14, 2022
Biogen partner Eisai issued a statement on January 13 strongly opposing a Medicare proposal earlier this week to limit coverage for the companies’ Alzheimer’s drug Aduhelm (aducanumab) to patients who will be enrolled in clinical trials designed for evidence development...read more